BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 14, 2010
 |  BC Week In Review  |  Company News  |  Other News

Myriad Pharmaceuticals cancer news

Myriad restructured and reduced headcount by 21 (13%) to about 140 to focus on its cancer pipeline. The company's lead cancer compound is Azixa, a small molecule microtubule destabilizing apoptosis-inducer in Phase II testing for metastatic melanoma and recurrent glioblastoma multiforme. Myriad also has MPC-3100, a fully-synthetic,...

Read the full 235 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >